Effect of BBP162 on praeputium eversion of Biomphalaria straminea

Diana Viray, Edwin ten Winkel

The effect of BBP162, a new selective serotonin reuptake inhibitor, on reproductive behaviour on snails was tested on the snail Biomphalaria straminae.

Snails were placed in solutions of BBP162 of ascending strength (2, 5 and 10 μM).

All snails showed praeputium eversion within 10 hours and developed erections. After 72 hours erections started to fade.

MED ≤ 2μM as all snails on the lowest dose showed significant effect.

Ref.:

• G. Nentwig: Another Example of Effects of Pharmaceuticals on Aquatic Invertebrates: Fluoxetine and Ciprofloxacin. In: Pharmaceuticals in the Environment (Ed: Klaus Kümmerer): Pub: Springer Berlin Heidelberg, 2008, Ch. 13
• Fong, Olex, Farrell, Majcharzak, Muschamp: Induction of preputium eversion by peptides, serotonin receptor antagonists, and selective serotonin reuptake inhibitors in Biomphalaria glabrata. Invertebrate Biology. V124, 4. P296-302
• Gust, Buronfosse, Giamberini, Ramil, Mons and Garric: Effects of fluoxetine on the reproduction of two prosobranch mollusks: Potamopyrgus antipodarum and Valvata piscinalis. Environmental Pollution Volume 157, Issue 2, February 2009, Pages 423-429

Effect of Durogesic® (fentanyl patch) compared to BBP 492 (chemically synthetised tetrodoxin derivative) on cancer related pain

Diana Viray, Edwin ten Winkel

BBP492 is a tetrodotoxin like compound that is not identical to any known natural occuring tetrodotoxin compound. In a phase II trial effects of Durogesic® patches on pain in cancerpatients were compared to BBP 492.

Both groups could use oxycodon against 'breakthrough' pain.

On a VAS, patients on BBP492 scored significantly better on pain control than patients on Durogesic® when compared to baseline. Also, patients on BBP 492 had significantly lower need for use of oxycodon during the trial.

 

Durogesic® is a brand name of Janssen-Cilag